Séminaire sur “In vitro evaluation of novel antimalarial compounds in the context of P. falciparum multiresistance”, par Flore Nardela
The Committee of Scientific Animation of Institut Pasteur du Cambodge ([email protected]
Thursday 7th of April 2016
At 14h00 in Administration room of Institut Pasteur du Cambodge, 1st floor
In vitro evaluation of novel antimalarial compounds in the context of P. falciparum multiresistance
by Flore Nardela
Institut Pasteur du Cambodge
Malaria is the deadliest parasitic disease with 584.000 deaths in 2013 and 198 million estimated cases worldwide. While this number is decreasing each year, thanks to an expansion in malaria interventions and the use of artemisinin derivatives, drug-resistances are a major threat to the progresses made. In areas along the Cambodia–Thailand border, P. falciparum has become resistant to most available antimalarial medicines, and multi-drug resistance is a major concern.
The current treatment policy is to use an Artemisinin-based Combination Therapy (ACT) which combines a fast acting drug—artemisinin derivative—with a long-lasting partner drug such as mefloquine, piperaquine, amodiaquine or lumefantrine. While partner drugs were supposed to limit the apparition of resistances, parasites resistant to both artemisinin and partner drug have emerged and spread in Cambodia.
The objective of this study was to investigate about the in vitro efficacy of novel antimalarial drugs in the current context of multidrug resistance.